tiprankstipranks
Ryman Healthcare Ltd. (RHCGF)
OTHER OTC:RHCGF
US Market
Want to see RHCGF full AI Analyst Report?

Ryman Healthcare (RHCGF) Earnings Dates, Call Summary & Reports

13 Followers

Earnings Data

Report Date
May 26, 2026
TBA (Confirmed)
Period Ending
2026 (Q4)
Consensus EPS Forecast
Last Year’s EPS
-0.44
Same Quarter Last Year
Based on 1 Analysts Ratings

Earnings Call Summary

Q2 2026
Earnings Call Date:Nov 26, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The call conveys a constructive operational and financial turnaround: management delivered the first positive free cash flow in years, material revenue growth (+13%), notable EBITDAF improvement and decisive cost‑out and refinancing actions that materially strengthen the balance sheet and lower interest costs. At the same time, challenges remain around resales margins, elevated bought‑back inventory (~$330m), weaker Auckland market exposure (~30% of portfolio), negative EPS driven by valuation volatility, and FX headwinds. Management has increased cost savings targets, confirmed sales guidance (1,300–1,400 RV units) and signalled further strategic detail at an upcoming Investor Day, suggesting confidence in continued recovery while acknowledging inventory and market risks.
Company Guidance
Ryman updated FY26 guidance and capital plans: full‑year RV sales are guided to 1,300–1,400 units, build‑rate guidance sits at the top end of 330 units/beds, and the cost‑out target has been increased to $50–$60m annualised (having delivered ~$40m annualised to 30 Sept); CapEx guidance was moderated after release of contingencies on completed projects and no recovery in Auckland (~30% of the portfolio) was assumed. Key operating and balance‑sheet metrics underpinning the guidance include H1 sales of 704 (with occupied sales up +12% in Q1 and +9% in Q2), positive free cash flow of $56.2m, total revenue up 13%, ~81‑unit gap between sales and turnover in H1, $330m of bought‑back resale stock and ~$470m of new‑sales stock (material cash‑release opportunity), a $376m independently valued land bank and recent land disposals of $42m (Park Terrace) and $35m (Mount Eliza) plus $33m contracted sales; the business also cites ~$1bn of unrealised development assets. The balance sheet has been reset with a completed refinancing extending average facility tenor to ~5 years, >$500m headroom, an ICR covenant of 1.50x (first testing Sep‑2026), ~70% of drawn debt on fixed rates (avg hedge tenor 3 years) and ~NZ$67m of annualised interest savings; an Investor Day in February will set out the refreshed strategy and new capital management framework (including dividend policy).
Cost-Out Progress and Upgraded Target
Implemented $40 million of annualised cost savings by 30 Sept and increased the FY target to $50–$60 million (from prior expectations), with non‑village expenses down 27% half‑on‑half to $54 million.
Successful Bank Refinancing and Treasury Improvements
Completed full refinancing, extending average facility tenor to ~5 years (no maturities until FY31), improved pricing and covenants, >$500 million funding headroom; ~70% of drawn debt fixed and ~$67 million annualised interest savings delivered post equity raise.
Sales Momentum and Guidance
Sales rebuilding with 704 total sales in the half, two quarters of sequential growth in occupied sales (Q1 +12%, Q2 +9% step-ups) and updated full‑year RV sales guidance raised to 1,300–1,400 units.
Pricing Enhancements and Front‑Book Upside
New pricing model largely in place: ~75% of new residents on the standard 30% DMF; average weekly fees have seen a ~60% uplift on rollover; front‑book revenue profile materially higher than back book, creating future earnings potential.
Balance Sheet and Portfolio Actions
Land bank independently valued at $376 million; completed divestments of Park Terrace ($42m) and Mount Eliza ($35m) plus other contracted sales totalling $110 million, and ~$470 million of new sales stock presents cash release opportunities.
Operational & Strategic Progress
Appointment of a Chief Development & Property Officer to support disciplined growth; continued external awards and improving internal customer survey results; investor day announced for February to present strategy refresh and capital management framework.
Positive Free Cash Flow
First positive free cash flow in more than a decade: free cash flow of $56.2 million for the half, supported by strong net development cash flows and lower finance costs.
Revenue Growth
Total revenue up 13% for the half driven by pricing and occupancy growth; resident base volume up ~4% year-on-year.
Operating EBITDAF Improvement
Operating EBITDAF increased to $40.1 million, a year‑on‑year lift of $26.4 million, reflecting revenue gains and disciplined cost control.
Material Reduction in Losses
Losses before tax and fair value movements reduced by $57.6 million year‑on‑year, demonstrating meaningful improvement in overall financial performance.

Ryman Healthcare (RHCGF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

RHCGF Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 26, 2026
2026 (Q4)
- / -
-0.436
Nov 26, 2025
2026 (Q2)
- / -0.03
0.077-133.77% (-0.10)
May 29, 2025
2025 (Q4)
- / -0.44
-0.15-190.67% (-0.29)
Nov 27, 2024
2025 (Q2)
- / 0.08
0.154-50.00% (-0.08)
May 26, 2024
2024 (Q4)
- / -0.15
0.064-334.38% (-0.21)
Nov 28, 2023
2024 (Q2)
- / 0.15
0.214-28.04% (-0.06)
May 18, 2023
2023 (Q4)
- / 0.06
0.493-87.02% (-0.43)
Nov 17, 2022
2023 (Q2)
- / 0.21
0.348-38.51% (-0.13)
May 19, 2022
2022 (Q4)
- / 0.49
0.25891.09% (+0.23)
Nov 18, 2021
2022 (Q2)
- / 0.35
0.23846.22% (+0.11)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

RHCGF Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 26, 2025
$1.75$1.750.00%
May 29, 2025
$1.41$1.410.00%
Nov 27, 2024
$2.67$2.75+2.77%
Nov 28, 2023
$3.05$3.02-0.89%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Ryman Healthcare Ltd. (RHCGF) report earnings?
Ryman Healthcare Ltd. (RHCGF) is schdueled to report earning on May 26, 2026, TBA (Confirmed).
    What is Ryman Healthcare Ltd. (RHCGF) earnings time?
    Ryman Healthcare Ltd. (RHCGF) earnings time is at May 26, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is RHCGF EPS forecast?
          Currently, no data Available